Home / Private raises / Mosaic Biosciences, Inc.
Mosaic Biosciences, Inc.
Biotechnology · Boulder, Colorado · $3.0M sold across 1 offering
Form D filings (1)
| Filed | Form | Sold | Offered | Investors | Exemption | Securities | First sale | |
|---|---|---|---|---|---|---|---|---|
| 2026-11-19 | D (new) | $3.0M | $3.0M | 3 | 506(b) | Equity | Oct 14 | SEC ↗ |
An update (D/A) restates the running total of its offering, so the total above counts each offering's latest figure once.
Issuer
| Industry | Biotechnology |
| Located | Boulder, Colorado |
| Entity | Corporation |
| Incorporated | Delaware |
| SEC CIK | 1526054 |
People named in the latest filing
| Name | Role |
|---|---|
| Martin Stanton | Director |
| Eric Furfine | Executive Officer, Director |
| Dan Mitchell | Director |
| Jeanette W. Welsh | Director |
| Rob J. Capone | Director |
| Jean-Pierre Wery | Executive Officer, Director |
| Deval Lashkari | Dr. Lashkari was elected a director in connection with the closing of the Offering. |
| Brooke Delgado | Executive Officer |
Names and roles as filed with the SEC. Addresses are not shown.
Source: SEC EDGAR Form D filings. Amounts are self-reported by the issuer. Not investment advice.
How are we doing?
